美国血液技术(HAE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

HAE 美国血液技术

盘后交易 05-04 16:59:45 EDT

55.32

-3.94

-6.65%

盘后55.32

+0.000.00%

16:48 EDT

最高59.15	最低55.15	成交量86.59万
今开58.98	昨收59.26	日振幅6.74%
总市值25.71亿	流通市值25.71亿	总股本4,647万
成交额4,843万	换手率1.86%	流通股本4,647万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"HAE","market":"US","secType":"STK","nameCN":"美国血液技术","latestPrice":55.32,"timestamp":1777924800000,"preClose":59.26,"halted":0,"volume":865856,"hourTrading":{"tag":"盘后","latestPrice":55.32,"preClose":55.32,"latestTime":"16:48 EDT","volume":37457,"amount":2072120.940344,"timestamp":1777927705894,"change":0,"changeRate":0,"amplitude":0.005604},"delay":0,"changeRate":-0.0664866689166385,"floatShares":46471350,"shares":46471350,"eps":3.651763,"marketStatus":"盘后交易","change":-3.94,"latestTime":"05-04 16:59:45 EDT","open":58.98,"high":59.145,"low":55.15,"amount":48431702.98208,"amplitude":0.067415,"askPrice":56.4,"askSize":35,"bidPrice":55.4,"bidSize":400,"shortable":3,"etf":0,"ttmEps":3.651763,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1777939200000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":673761600000,"exchange":"NYSE","adjPreClose":59.26,"postHourTrading":{"tag":"盘后","latestPrice":55.32,"preClose":55.32,"latestTime":"16:48 EDT","volume":37457,"amount":2072120.940344,"timestamp":1777927705894,"change":0,"changeRate":0,"amplitude":0.005604},"volumeRatio":1.540939,"impliedVol":0.6239,"impliedVolPercentile":0.9084},"requestUrl":"/m/hq/s/HAE","defaultTab":"news","newsList":[{"id":"1115190387","title":"美国血液技术Vascade MVP® XL静脉血管闭合系统获FDA扩大适应症批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1115190387","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115190387?lang=zh_cn&edition=full","pubTime":"2026-03-31 04:16","pubTimestamp":1774901781,"startTime":"0","endTime":"0","summary":"美国血液技术公司宣布，其Vascade MVP® XL静脉血管闭合系统已获得美国食品药品监督管理局的扩大标签使用批准。这一监管里程碑意味着该创新器械的应用范围将进一步拓展，为更多患者提供微创手术后的血管闭合解决方案。\n此次标签扩展彰显了公司在血管闭合技术领域的持续创新能力，也为临床医生提供了更灵活的手术工具选择。该系统采用独特的闭合机制，能够有效提升手术效率并降低并发症风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","IE00B19Z6F94.USD","IE00B64QTZ34.USD","LU0205193047.USD","LU0012050646.USD","LU0106261612.USD","IE0034390439.USD","LU1169590202.USD","LU0205194284.USD","HAE","BK4198","IE00BLDYK493.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617470265","title":"Kalvista Pharmaceuticals, Inc.盘中异动 快速上涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617470265","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617470265?lang=zh_cn&edition=full","pubTime":"2026-03-04 23:37","pubTimestamp":1772638656,"startTime":"0","endTime":"0","summary":"北京时间2026年03月04日23时37分，Kalvista Pharmaceuticals, Inc.股票出现波动，股价急速上涨5.06%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.65%。其相关个股中，Can Fite Biopharma Ltd、Moolec Science Sa C/Wts 30/01/2028、Klotho Neurosciences Inc C/Wts 21/06/2029 涨幅较大，Can Fite Biopharma Ltd、Klotho Neurosciences, Inc.、Onconetix, Inc.较为活跃，换手率分别为2160.20%、58.17%、48.98%，振幅较大的相关个股有Moolec Science Sa C/Wts 30/01/2028、Klotho Neurosciences, Inc.、Can Fite Biopharma Ltd，振幅分别为114.71%、51.24%、41.60%。Kalvista Pharmaceuticals, Inc.公司简介：KalVista Pharmaceuticals Inc 是一家制药公司，为未满足需求的患有罕见疾病的患者开发并提供口服疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304233737a6a2c08b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304233737a6a2c08b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1169590202.USD","KALV","LU0205194284.USD","LU0205193047.USD","IE00B64QTZ34.USD","LU1169589451.USD","LU0106261612.USD","LU0012050646.USD","IE00BLDYK493.USD","HAE","BK4198","BK4139","IE00B19Z6F94.USD","IE0034390439.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186396301","title":"美国血液技术Nexsys® PCS血浆采集系统及Persona® Plus技术获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1186396301","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186396301?lang=zh_cn&edition=full","pubTime":"2026-02-24 05:17","pubTimestamp":1771881434,"startTime":"0","endTime":"0","summary":"美国血液技术公司宣布，其整合了Persona® Plus技术的Nexsys® PCS血浆采集系统已正式获得美国食品药品监督管理局的上市许可。这一关键监管批准为该公司在血浆采集领域的创新产品商业化铺平了道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","IE00BLDYK493.USD","LU0012050646.USD","LU0106261612.USD","HAE","IE0034390439.USD","LU0205194284.USD","IE00B19Z6F94.USD","LU1169590202.USD","LU1169589451.USD","IE00B64QTZ34.USD","LU0205193047.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192031118","title":"美国血液技术公布2026财年第三季度财务报告，投资者关系网站可查阅","url":"https://stock-news.laohu8.com/highlight/detail?id=1192031118","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192031118?lang=zh_cn&edition=full","pubTime":"2026-02-05 19:06","pubTimestamp":1770289564,"startTime":"0","endTime":"0","summary":"美国血液技术（Haemonetics Corporation）已正式发布其2026财年第三季度的财务业绩报告。\n相关财务数据及详细信息现已在该公司的投资者关系网站上公布，供投资者及利益相关方查阅。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HAE","LU1169589451.USD","LU0012050646.USD","LU0205193047.USD","IE00B64QTZ34.USD","LU0205194284.USD","IE00BLDYK493.USD","LU1169590202.USD","LU0106261612.USD","BK4198","IE00B19Z6F94.USD","IE0034390439.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143603106","title":"财报前瞻｜美国血液技术本季度营收预计降至3.32亿美元，看多观点占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1143603106","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143603106?lang=zh_cn&edition=full","pubTime":"2026-01-29 11:17","pubTimestamp":1769656630,"startTime":"0","endTime":"0","summary":"美国血液技术将在2026年02月05日发布财报，市场关注营收与盈利结构变化及主要业务恢复节奏。市场一致预期本季度美国血液技术总收入为3.32亿美元，同比下降6.04%；EBIT为8,875.08万美元，同比预计增长3.76%；调整后每股收益为1.25美元，同比预计增长6.84%。多家机构在近期前瞻中强调：在收入同比压力下，利润率修复与费用管控带来每股收益的韧性，上一季度EPS为1.27美元高于市场预测，本季度一致预期EPS为1.25美元，若毛利率维持高位，EBIT有望小幅增长至8,875.08万美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜美国血液技术本季度营收预计降至3.32亿美元，看多观点占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HAE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603653069","title":"Kalvista Pharmaceuticals, Inc.盘中异动 股价大跌5.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603653069","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603653069?lang=zh_cn&edition=full","pubTime":"2026-01-14 00:29","pubTimestamp":1768321774,"startTime":"0","endTime":"0","summary":"北京时间2026年01月14日00时29分，Kalvista Pharmaceuticals, Inc.股票出现异动，股价快速跳水5.25%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.30%。其相关个股中，Xtl生物制药、Decoy Therapeutics Inc.、Briacell Therapeutics Corp.涨幅较大，Decoy Therapeutics Inc.、Scisparc Ltd.、Briacell Therapeutics Corp.较为活跃，换手率分别为1393.28%、1174.36%、334.36%，振幅较大的相关个股有Xtl生物制药、Lexaria Bioscience Corp C/Wts 14/01/2026 、Decoy Therapeutics Inc.，振幅分别为96.62%、67.92%、41.72%。Kalvista Pharmaceuticals, Inc.公司简介：KalVista Pharmaceuticals Inc 是一家制药公司，为未满足需求的患有罕见疾病的患者开发并提供口服疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114002935953ca0c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114002935953ca0c8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0106261612.USD","LU0012050646.USD","BK4139","IE00BLDYK493.USD","HAE","LU1169589451.USD","LU1169590202.USD","KALV","IE0034390439.USD","IE00B19Z6F94.USD","LU0205194284.USD","BK4198","IE00B64QTZ34.USD","LU0205193047.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603892046","title":"Kalvista Pharmaceuticals, Inc.盘中异动 早盘快速下跌5.00%报15.96美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603892046","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603892046?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:46","pubTimestamp":1768229172,"startTime":"0","endTime":"0","summary":"北京时间2026年01月12日22时46分，Kalvista Pharmaceuticals, Inc.股票出现异动，股价大幅下跌5.00%。Kalvista Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.06%。其相关个股中，Cdt Equity Inc C/Wts 22/09/2028、Day One Biopharmaceuticals, Inc.、Forte Biosciences, Inc.涨幅较大，Jaguar Health, Inc.、Osr Holdings, Inc.、Genprex, Inc.较为活跃，换手率分别为539.57%、112.53%、53.83%，振幅较大的相关个股有Pyxis Oncology, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Geovax Labs, Inc.，振幅分别为26.42%、25.56%、24.64%。Kalvista Pharmaceuticals, Inc.公司简介：KalVista Pharmaceuticals Inc 是一家制药公司，为未满足需求的患有罕见疾病的患者开发并提供口服疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112224613a7120f54&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112224613a7120f54&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0012050646.USD","IE0034390439.USD","KALV","LU1169589451.USD","LU1169590202.USD","BK4198","LU0205193047.USD","LU0205194284.USD","LU0106261612.USD","IE00B19Z6F94.USD","BK4139","HAE","IE00BLDYK493.USD","IE00B64QTZ34.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179349578","title":"Orchestra BioMed将因美国血液技术收购Vivasure获得最高2100万美元收益","url":"https://stock-news.laohu8.com/highlight/detail?id=1179349578","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179349578?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:01","pubTimestamp":1768226511,"startTime":"0","endTime":"0","summary":"美国血液技术（Haemonetics）对Vivasure的收购案，将为Orchestra BioMed带来最高达2100万美元的资金流入。这一交易预计显著增强Orchestra BioMed的现金流状况，为其后续业务拓展提供重要支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0205193047.USD","LU1169589451.USD","BK4198","IE00B19Z6F94.USD","IE0034390439.USD","LU1169590202.USD","HAE","LU0012050646.USD","IE00B64QTZ34.USD","LU0106261612.USD","LU0205194284.USD","OBIO","IE00BLDYK493.USD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129511852","title":"Vivasure达成里程碑协议 交易价值最高可达1.85亿欧元（约合2.15亿美元）","url":"https://stock-news.laohu8.com/highlight/detail?id=1129511852","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129511852?lang=zh_cn&edition=full","pubTime":"2026-01-09 21:04","pubTimestamp":1767963857,"startTime":"0","endTime":"0","summary":"医疗科技公司Vivasure近日宣布达成一项重大交易协议。根据协议条款，该交易在完成特定里程碑后，总价值最高可达1.85亿欧元（约2.15亿美元）。\n此次交易的核心价值与实现预设里程碑直接挂钩。当Vivasure成功达成特定发展目标时，交易对价将逐步解锁。这种结构化安排既体现了对Vivasure技术价值的认可，也确保了交易各方利益的一致性。\n1.85亿欧元的最高估值反映了市场对Vivasure创新技术的强烈信心。该交易预计将为公司未来发展提供重要资金支持，同时可能带来战略合作机会。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64QTZ34.USD","IE0034390439.USD","LU0106261612.USD","LU0205193047.USD","LU0205194284.USD","IE00B19Z6F94.USD","LU1169590202.USD","LU0012050646.USD","HAE","LU1169589451.USD","IE00BLDYK493.USD","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190187758","title":"美国血液技术收购协议含附加条款：销售增长达标可获8500万欧元或有对价","url":"https://stock-news.laohu8.com/highlight/detail?id=1190187758","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190187758?lang=zh_cn&edition=full","pubTime":"2026-01-09 19:17","pubTimestamp":1767957442,"startTime":"0","endTime":"0","summary":"美国血液技术（Haemonetics）最新达成的收购协议中设置了一项弹性对价机制——若被收购方未来能达到预设的销售增长目标及其他特定里程碑，收购总价将额外增加8500万欧元。\n这项或有对价条款将交易金额与业绩表现直接挂钩，既为收购方控制了前期成本，又为被收购团队保留了业绩激励空间。交易结构反映出医疗科技行业并购中对长期价值评估的精细化趋势。\n业内人士指出，此类分层对价设计能有效平衡交易双方风险，尤其适用于创新技术企业的并购场景。随着医疗产业链整合加速，类似弹性支付方案或将成为行业标准配置。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64QTZ34.USD","LU1169590202.USD","IE00B19Z6F94.USD","IE0034390439.USD","LU0205193047.USD","HAE","IE00BLDYK493.USD","LU0106261612.USD","LU1169589451.USD","BK4198","LU0012050646.USD","LU0205194284.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190186517","title":"异动解读 | 美国血液技术股价大涨5.27%，受益于分析师上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1190186517","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190186517?lang=zh_cn&edition=full","pubTime":"2025-11-07 23:01","pubTimestamp":1762527715,"startTime":"0","endTime":"0","summary":"周五盘中，美国血液技术(HAE)股价大涨5.27%，引发市场关注。\n\n这一显著涨幅主要受益于分析师的积极评级。投资银行Needham上调了对美国血液技术的目标价，从68美元上调至78美元，提振了投资者信心。Needham的这一举动表明他们看好该公司未来的业务前景和增长潜力。\n\n美国血液技术是一家专注于血液和血浆管理解决方案的医疗技术公司。分析师目标价的上调可能反映了对公司产品需求增加、市场份额扩大或财务业绩改善的预期。这一利好消息推动投资者积极买入，从而带动股价在盘中显著上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["HAE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173492646","title":"异动解读 | 美国血液技术盘中大涨5.27%，Needham上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1173492646","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173492646?lang=zh_cn&edition=full","pubTime":"2025-11-07 23:01","pubTimestamp":1762527713,"startTime":"0","endTime":"0","summary":"美国血液技术（HAE）周五盘中大涨5.27%，截至发稿股价报价53.26美元。该股走强主要受益于华尔街知名投行Needham的看好。\n\n根据消息，Needham分析师上调了美国血液技术的目标价，从此前的68美元上调至78美元，涨幅达14.7%。分析师表示，对公司未来业务增长前景更加乐观，认为公司在血液采集和处理设备领域的领先地位将持续带来收入增长。\n\n美国血液技术是全球领先的血液管理解决方案供应商，专注于为医疗机构提供血液采集、处理和血浆收集等设备和耗材。Needham分析师的上调目标价显示出对公司基本面和长期发展的信心，这也提振了投资者对该股的热情，推动股价强劲上涨。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["HAE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160884303","title":"美国血液技术：美银全球研究将评级从“跑输大盘”上调至“中性”；目标价从58美元上调至75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1160884303","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160884303?lang=zh_cn&edition=full","pubTime":"2025-11-07 22:43","pubTimestamp":1762526615,"startTime":"0","endTime":"0","summary":"美国血液技术：美银全球研究将评级从“跑输大盘”上调至“中性”；目标价从58美元上调至75美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLDYK493.USD","LU0012050646.USD","LU1169589451.USD","LU0106261612.USD","BK4198","HAE","IE0034390439.USD","LU0205193047.USD","LU0205194284.USD","LU1169590202.USD","IE00B64QTZ34.USD","IE00B19Z6F94.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514086737","title":"美国血液技术盘中异动 下午盘急速上涨5.00%报66.17美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514086737","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514086737?lang=zh_cn&edition=full","pubTime":"2025-02-25 03:53","pubTimestamp":1740426800,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日03时53分，美国血液技术股票出现异动，股价快速拉升5.00%。截至发稿，该股报66.17美元/股，成交量38.3166万股，换手率0.76%，振幅5.12%。美国血液技术股票所在的医疗设备行业中，整体涨幅为0.25%。其相关个股中，Anbio Biotechnology、奥瑞许科技、美国血液技术涨幅较大，Sharps Technology Inc.、Glucotrack, Inc.、Microbot Medical Inc.较为活跃，换手率分别为44.95%、6.01%、5.07%，振幅较大的相关个股有Sharps Technology Inc.、Nexgel Inc C/Wts 27/12/2026 、Precision Optics Corporation, Inc.，振幅分别为23.85%、15.98%、14.07%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225035320a25257e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225035320a25257e2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0106261612.USD","LU1169590202.USD","IE00B64QTZ34.USD","LU0205194284.USD","LU0205193047.USD","IE00BLDYK493.USD","BK4198","HAE","LU1169589451.USD","LU0012050646.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155255330","title":"异动解读 | 美国血液技术公司股价盘中大跌5.25% 分析师下调评级预期所致","url":"https://stock-news.laohu8.com/highlight/detail?id=1155255330","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155255330?lang=zh_cn&edition=full","pubTime":"2025-02-08 03:26","pubTimestamp":1738956391,"startTime":"0","endTime":"0","summary":"美国血液技术公司今日盘中股价大跌5.25%,引发了市场的广泛关注。根据相关新闻报道,导致该公司股价下跌的主要原因是分析师对其未来前景的预期下调。知名投资银行摩根大通证券公司今日维持了对美国血液技术的\"优于大市\"评级,但将公司的目标股价从125美元下调至100美元。美国血液技术公司主要从事血液和血浆成分采集、加工和输送,业务分为血浆、血液中心和医院三个分部。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 美国血液技术公司股价盘中大跌5.25% 分析师下调评级预期所致","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["HAE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509778144","title":"美国血液技术盘中异动 下午盘大幅跳水5.06%报59.80美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509778144","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509778144?lang=zh_cn&edition=full","pubTime":"2025-02-08 03:15","pubTimestamp":1738955721,"startTime":"0","endTime":"0","summary":"北京时间2025年02月08日03时15分，美国血液技术股票出现波动，股价快速下跌5.06%。截至发稿，该股报59.80美元/股，成交量146.523万股，换手率2.92%，振幅6.33%。美国血液技术股票所在的医疗设备行业中，整体跌幅为0.68%。美国血液技术公司简介：美国血液技术公司旨在通过在血液和血浆成分采集、外科病房和医院输血服务空间提供医疗产品和解决方案，改善患者护理，降低医疗保健成本。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208031521a23d5d8f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208031521a23d5d8f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1169590202.USD","LU1169589451.USD","IE00B64QTZ34.USD","LU0012050646.USD","LU0205194284.USD","HAE","BK4198","LU0106261612.USD","LU0205193047.USD","IE00BLDYK493.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509729791","title":"摩根大通证券公司：维持Haemonetics(HAE.US)评级，由优于大市调整至优于大市评级, 目标价由125.00美元调整至100.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509729791","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509729791?lang=zh_cn&edition=full","pubTime":"2025-02-08 01:02","pubTimestamp":1738947740,"startTime":"0","endTime":"0","summary":"摩根大通证券公司：维持Haemonetics(HAE.US)评级，由优于大市调整至优于大市评级, 目标价由125.00美元调整至100.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/08010248031451.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["399975","159848","HAE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509572976","title":"雷蒙德詹姆斯公司：重申Haemonetics(HAE.US)评级，由强烈买入调整至强烈买入评级, 目标价由120.00美元调整至115.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509572976","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509572976?lang=zh_cn&edition=full","pubTime":"2025-02-08 01:02","pubTimestamp":1738947740,"startTime":"0","endTime":"0","summary":"雷蒙德詹姆斯公司：重申Haemonetics(HAE.US)评级，由强烈买入调整至强烈买入评级, 目标价由120.00美元调整至115.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/08010248031449.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["HAE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111478372","title":"异动解读 | 美国血液技术因下调业绩预期 盘中一度大跌近11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1111478372","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111478372?lang=zh_cn&edition=full","pubTime":"2025-02-06 23:42","pubTimestamp":1738856552,"startTime":"0","endTime":"0","summary":"美国医疗设备制造商美国血液技术(HAE)2月6日盘中一度大跌10.74%,引发市场关注。\n\n公司当天公布下调了2025财年的预期销售增长率,从此前的5%-8%下调至3%-5%,这是导致该股大跌的主因。同时,公司第三季度的营收3.49亿美元也低于分析师预期的3.53亿美元。\n\n美国血液技术主营业务包括血液和血浆成分采集、外科手术室和医院输血服务等。公司去年第三季度每股利润1.19美元高于市场预期,但由于业绩预期的下调,导致投资者对其长期增长前景持谨慎态度。该股过去12个月股价已下跌约17%。机构评级显示,82%的分析师给予买入评级,主要看好其血浆和医院业务增长潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["HAE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509774312","title":"美国血液技术盘中异动 急速下跌8.80%报64.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509774312","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509774312?lang=zh_cn&edition=full","pubTime":"2025-02-06 22:32","pubTimestamp":1738852370,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日22时32分，美国血液技术股票出现波动，股价快速下挫8.80%。截至发稿，该股报64.97美元/股，成交量2.4341万股，换手率0.05%，振幅1.01%。美国血液技术股票所在的医疗设备行业中，整体跌幅为0.19%。美国血液技术公司简介：美国血液技术公司旨在通过在血液和血浆成分采集、外科病房和医院输血服务空间提供医疗产品和解决方案，改善患者护理，降低医疗保健成本。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223250a23bce9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223250a23bce9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1169589451.USD","IE00B64QTZ34.USD","BK4198","HAE","LU1169590202.USD","IE00BLDYK493.USD","LU0205194284.USD","LU0106261612.USD","LU0205193047.USD","LU0012050646.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.haemonetics.com","stockEarnings":[{"period":"1week","weight":-0.0112},{"period":"1month","weight":0.0537},{"period":"3month","weight":-0.111},{"period":"6month","weight":0.185},{"period":"1year","weight":-0.0592},{"period":"ytd","weight":-0.2606}],"compareEarnings":[{"period":"1week","weight":0.0094},{"period":"1month","weight":0.0998},{"period":"3month","weight":0.0414},{"period":"6month","weight":0.0566},{"period":"1year","weight":0.2904},{"period":"ytd","weight":0.0568}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Haemonetics Corporation1971年根据马萨诸塞州的法律注册成立，是一个全球性医疗设备公司,致力于为客户提供创新的血液管理解决方案——血浆来源收集者,采血机构和医院,在输血行业医疗设备系统方面有着强大的品牌优势,为客户提供解决方案的同时还提供信息技术平台和增值服务,其解决方案帮助患者改善临床结果，并提高血液中的供应链效率。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.02136},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.014099},{"month":3,"riseRate":0.657143,"avgChangeRate":0.017598},{"month":4,"riseRate":0.485714,"avgChangeRate":-0.022035},{"month":5,"riseRate":0.514286,"avgChangeRate":0.016752},{"month":6,"riseRate":0.6,"avgChangeRate":0.021703},{"month":7,"riseRate":0.657143,"avgChangeRate":0.018045},{"month":8,"riseRate":0.714286,"avgChangeRate":0.021344},{"month":9,"riseRate":0.514286,"avgChangeRate":0.013166},{"month":10,"riseRate":0.514286,"avgChangeRate":-0.005196},{"month":11,"riseRate":0.542857,"avgChangeRate":0.046958},{"month":12,"riseRate":0.571429,"avgChangeRate":0.023019}],"exchange":"NYSE","name":"美国血液技术","nameEN":"Haemonetics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"美国血液技术(HAE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供美国血液技术(HAE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"美国血液技术,HAE,美国血液技术股票,美国血液技术股票老虎,美国血液技术股票老虎国际,美国血液技术行情,美国血液技术股票行情,美国血液技术股价,美国血液技术股市,美国血液技术股票价格,美国血液技术股票交易,美国血液技术股票购买,美国血液技术股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"美国血液技术(HAE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供美国血液技术(HAE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}